informCLL™:

A Disease Registry for Patients With Chronic Lymphocytic Leukemia

About this Trial

A multicenter, prospective, observational registry of CLL patients who are initiating approved oral kinase inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient characteristics, healthcare resource utilization, and clinical outcomes, as well as patient-reported outcome (PRO) measures. 

• Status: Enrolling now
• Location: Atrium Medical Center
• Study type: Observational
• Ages eligible for study: 18 years and older
• Genders eligible for study: Both
• Principal Investigator: Dr. Nikki Okoye
• For more information about this study, visit ClinicalTrials.gov: NCT02582879

Contact Us

If you would like information about participating in this study, contact:

Sandy Fletcher, BSN, RN, CNOR, OCN, CCRP
(513) 420-5674
slfletcher@premierhealth.com